Clinical significance of NUCB2 mRNA expression in prostate cancer.
about
Association between NQO1 C609T polymorphism and prostate cancer riskOverexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancerHigh NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patientsProtein tyrosine kinase 7 (PTK7) as a predictor of lymph node metastases and a novel prognostic biomarker in patients with prostate cancer.Association between interleukin-4 gene intron 3 VNTR polymorphism and cancer risk.Association between IL-4 -590C>T polymorphism and gastric cancer risk.Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma.Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expressionMicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma.Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer.Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.Expression of RABEX-5 and its clinical significance in prostate cancer.The prognostic value of elevated ezrin in patients with osteosarcoma.Lack of association between methylenetetrahydrofolate dehydrogenase 1 G1958A polymorphism and prostate cancer risk: a meta-analysis.Lack of association between interleukin-4 -524C>T polymorphism and colorectal cancer susceptibility.Lack of association between IL-4 -588C>T polymorphism and NHL susceptibility.Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer.Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomyAssociation between IRS-1 Gly972Arg polymorphism and colorectal cancer risk.The prognostic value of Smad4 mRNA in patients with prostate cancer.Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.Association between IL-4 -589C>T polymorphism and colorectal cancer risk.Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma.A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma.High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer.Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.Association between interleukin-4 -590C > T polymorphism and non-Hodgkin's lymphoma risk.High NUCB2 expression level is associated with metastasis and may promote tumor progression in colorectal cancer.Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer
P2860
Q28240340-3116E71C-A397-404B-8B97-D6CE45266519Q28541215-3FAC5134-5581-44D5-863B-8B7272A3D83AQ33798805-66D4E05E-3D76-4473-9ECD-276F2796BBEFQ34072263-3A3374B0-12F2-47A2-9FE5-E7336F6C133EQ34643517-FAA95C18-E0FF-4739-8C27-B07BA4CCB22DQ35000510-B372E9F6-8122-4EE0-ABB1-30523342C76AQ35033273-E9B8D9EB-73C1-43F3-B07F-BFF041355B75Q35056269-AC15C0ED-4CBB-40C7-A233-3BB58475931AQ35742473-D7938C74-2833-4E77-8EEA-549FD22D3632Q36025254-03EADB5E-2E3E-448B-AD56-9FF5B48E13F0Q37327751-03873E36-8E87-4D45-8BD9-69192E5394A3Q37367755-916C496B-156B-43B9-9D51-90BC952FB0CFQ37718867-C3CD58F0-A8EA-4A05-B7C1-F4C9BD602DD9Q38135314-EA6CDF48-6FEB-492E-B5B1-B82046B3D037Q38160390-08E41219-375D-43F8-AAC5-C29A06BAE7C6Q38169608-529D0D16-8F2A-47E8-AFEB-BDA972E98480Q38181968-FE5B4DBB-343A-4D55-9DE0-3C2DBEB20302Q41721639-960FC0A0-B129-4CC4-B5FB-03C1FD781B89Q41910716-41C98724-05D8-4D6C-B50F-5BF76920175DQ42804845-33E979C9-DD9B-4844-889C-BC1D0C0CACFAQ44635848-FC7A6100-7FE6-4A53-8477-216A01CC3AB6Q44984281-8731CC0A-969F-4F34-852A-05FCD58478F2Q46632048-822ABC19-DAD8-400D-830A-66BDE07CB703Q46735674-9A52C7FF-8A30-4D6D-8E27-8F1A23523EE3Q46838376-3A9FD5A4-3294-46C9-9DDD-1906437F9B3CQ49729051-94017D90-8341-4250-A3F4-72AF2E95D1FCQ50886981-91042CFC-AD77-4C7C-99CF-D1A51A83715FQ53134069-CD15BCD3-F3E8-4F72-A062-1BF5B48E0386Q54542309-62DFA6E9-60A8-4041-831C-437F35EF4820Q55310865-209F8C59-4426-4635-9155-52340257E6DBQ57492929-D1A6480B-E3DD-4BBA-94D9-6FD8B8986C90
P2860
Clinical significance of NUCB2 mRNA expression in prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical significance of NUCB2 mRNA expression in prostate cancer.
@en
Clinical significance of NUCB2 mRNA expression in prostate cancer.
@nl
type
label
Clinical significance of NUCB2 mRNA expression in prostate cancer.
@en
Clinical significance of NUCB2 mRNA expression in prostate cancer.
@nl
prefLabel
Clinical significance of NUCB2 mRNA expression in prostate cancer.
@en
Clinical significance of NUCB2 mRNA expression in prostate cancer.
@nl
P2093
P2860
P356
P1476
Clinical significance of NUCB2 mRNA expression in prostate cancer.
@en
P2093
P2860
P2888
P356
10.1186/1756-9966-32-56
P577
2013-08-16T00:00:00Z
P5875
P6179
1033493872